Starting Lumvoa: setting expectations with your patient

Before starting your patient’s treatment¹

Review the full treatment schedule with your patient—5 infusions administered once every 3 weeks over a 12-week period 
Encourage your patient to plan ahead by confirming appointments and asking about arranging transportation and addressing work or caregiving coverage ahead of each office visit 
If your patient is enrolled in ViridianCares™, suggest that they connect with their Patient Access Liaison (PAL) for scheduling or affordability support

During your patient’s course of treatment¹

Remind your patient to eat well, drink plenty of fluids, and wear comfortable clothing with loose sleeves on the day of their infusion
Remind them that each Lumvoa™ (veligrotug-vvze) infusion lasts about 30 to 45 minutes
Monitor for infusion reactions during and immediately after each infusion. Remind your patient of the importance of immediately reporting any symptoms such as headache, chills, fatigue, fever, or changes in blood pressure
Provide patients with the Lumvoa Treatment Tracker to support engagement and adherence through all 5 infusions

Post-treatment care

Schedule your patient's next infusion and ask about any potential tolerability issues 
Ask patients to report any side effects or signs of worsening inflammatory bowel disease, changes in hearing, or elevated blood glucose levels
If your patient misses an infusion, work with them to reschedule as soon as possible
For your patients enrolled in ViridianCares, encourage them to follow up with their PAL to discuss any outstanding access or coverage issues

Find information and infusion resources for your practice

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see accompanying Full Prescribing Information.

Lumvoa™ (veligrotug-vvze). Prescribing Information. Viridian Therapeutics, Inc; 2026.